| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 27.08 | 31.5 | |
Op profit growth | 15.96 | 36.29 | |
EBIT growth | 21.33 | 33.81 | |
Net profit growth | 21.53 | 28.99 | |
Profitability ratios (%) | |||
OPM | 34.31 | 37.6 | 36.28 |
EBIT margin | 36.89 | 38.64 | 37.97 |
Net profit margin | 27.53 | 28.79 | 29.35 |
RoCE | 24.51 | 27.53 | |
RoNW | 4.63 | 5.21 | |
RoA | 4.57 | 5.12 | |
Per share ratios (₹) | |||
EPS | 73.75 | 60.94 | 49.88 |
Dividend per share | 0 | 0 | 0 |
Cash EPS | 67.03 | 54.9 | 43.77 |
Book value per share | 435.63 | 360.84 | 235.31 |
Valuation ratios | |||
P/E | 44.32 | 40.65 | |
P/CEPS | 48.76 | 45.13 | |
P/B | 7.5 | 6.86 | |
EV/EBIDTA | 29.19 | 26.11 | |
Payout (%) | |||
Dividend payout | 0 | 0 | 0 |
Tax payout | -25.13 | -25.31 | -22.15 |
Liquidity ratios | |||
Debtor days | 72.39 | 67.07 | |
Inventory days | 102.05 | 107.06 | |
Creditor days | -56.54 | -57.47 | |
Leverage ratios | |||
Interest coverage | -309.76 | -392.32 | -139.24 |
Net debt / equity | -0.43 | -0.5 | -0.36 |
Net debt / op. profit | -2.04 | -2.3 | -1.38 |
Cost breakup (₹) | |||
Material costs | -47.92 | -43.08 | -41.85 |
Employee costs | -7.69 | -8.99 | -10.54 |
Other costs | -10.06 | -10.32 | -11.32 |
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
Here are some of the stocks that may see significant price movement today: Tata Chemicals, Power Grid, Welspun Enterprises, etc.
EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) increased by 1% YoY to ₹360 crore, compared to ₹356.4 crore in the previous year.
Sintilimab is marketed in China as TYVYT (sintilimab injectable) and was co-developed by Innovent and Eli Lilly.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
